ArticleJournal of orthopaedic surgery and research2025
Targeting macrophage JAK3/STAT3 signaling with tectochrysin: a novel therapeutic strategy to ameliorate bone erosion and synovitis in rheumatoid arthritis.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tectochrysin alleviates Ang II-induced pathological cardiac hypertrophy by binding to STING and inhibiting STING/NFκB-mediated inflammation.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aims to clarify whether Tectochrysin has a therapeutic effect on rheumatoid arthritis animal models and to explore the potential therapeutic mechanisms.
methodsDBA mice were used to establish a collagen-induced arthritis mouse model. Then, we administered Tectochrysin via intragastric treatment at two doses of 5 mg/kg and 10 mg/kg. To evaluate the therapeutic effects, we assessed the clinical manifestations in mice, measured the levels of cytokines in mouse serum, performed pathological staining on knee and ankle joints, and analyzed bone destruction in knee and bone joints using micro-CT. Furthermore, combining molecular docking technology, we investigated the effects of Tectochrysin both in vitro and in vivo. In vitro experiments involved THP-1-induced macrophages, examining the impact of Tectochrysin on macrophages and CIA mouse peritoneal macrophages, as well as on JAK3 and STAT3 phosphorylation. We also analyzed the effects of Tectochrysin on the transcription levels of inflammatory factors in macrophages and on the migration of MH7A cells.
resultsOur study shows that Tectochrysin has a significant therapeutic effect on CIA mice. The clinical manifestations of CIA mice were alleviated after Tectochrysin administration, with reduced levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in the serum. Both the pathological staining of bone joints and the micro-CT results indicated less bone and cartilage damage in the Tectochrysin group. Additionally, Tectochrysin remarkably improved synovial hyperplasia and inflammatory cell infiltration in the joints of CIA mice.Molecular docking results revealed a more pronounced effect of Tectochrysin on JAK3. In both in vitro and vivo, Tectochrysin was found to inhibit the phosphorylation of JAK3 and STAT3, as well as the transcription of inflammatory cytokines in THP-1 derived macrophages.
conclusionTectochrysin may be a novel RA therapeutic agent, likely acting via macrophage JAK/STAT pathway inhibition, with promising clinical potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.